185 related articles for article (PubMed ID: 3882681)
21. Fluoxetine: clinical pharmacology and physiologic disposition.
Lemberger L; Bergstrom RF; Wolen RL; Farid NA; Enas GG; Aronoff GR
J Clin Psychiatry; 1985 Mar; 46(3 Pt 2):14-9. PubMed ID: 3871765
[TBL] [Abstract][Full Text] [Related]
22. Pharmaco-EEG profiles of antidepressants. Pharmacodynamic studies with fluvoxamine.
Saletu B; Grünberger J; Rajna P
Br J Clin Pharmacol; 1983; 15 Suppl 3(Suppl 3):369S-383S. PubMed ID: 6407499
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of encephalotropic and psychotropic properties of gabapentin in man by pharmaco-EEG and psychometry.
Saletu B; Grünberger J; Linzmayer L
Int J Clin Pharmacol Ther Toxicol; 1986 Jul; 24(7):362-73. PubMed ID: 3525428
[TBL] [Abstract][Full Text] [Related]
24. Classification and determination of cerebral biovailability of psychotropic drugs by quantitative "pharmaco-EEG" and psychometric investigations (studies with AX-A411-BS).
Saletu B; Grünberger J; Linzmayer L
Int J Clin Pharmacol Biopharm; 1977 Oct; 15(10):449-59. PubMed ID: 21853
[TBL] [Abstract][Full Text] [Related]
25. Determination of psychoactivity and cerebral bioavailability of danitracene (WA 335) by quantitative pharmaco-EEG and psychometric investigations.
Saletu B; Grünberger J; Flener R; Linzmayer L; Sieroslawski H
Curr Ther Res Clin Exp; 1976 Dec; 20(6):810-21. PubMed ID: 827426
[No Abstract] [Full Text] [Related]
26. Double-blind, placebo-controlled, multiple-ascending-dose study on the pharmacodynamics of ABIO-08/01, a new CNS drug with potential anxiolytic activity. 2. EEG-tomography findings based on LORETA (low-resolution brain electromagnetic tomography).
Saletu B; Anderer P; Wolzt M; Nosiska D; Assandri A; Noseda E; Nannipieri F; Saletu-Zyhlarz GM
Neuropsychobiology; 2009; 59(2):110-22. PubMed ID: 19365151
[TBL] [Abstract][Full Text] [Related]
27. On central effects of serotonin re-uptake inhibitors: quantitative EEG and psychometric studies with sertraline and zimelidine.
Saletu B; Grünberger J; Linzmayer L
J Neural Transm; 1986; 67(3-4):241-66. PubMed ID: 2949057
[TBL] [Abstract][Full Text] [Related]
28. CNS effects of citalopram, a new serotonin inhibitor antidepressant (a quantitative pharmaco-electroencephalography study).
Itil TM; Menon GN; Bozak MM; Itil KZ
Prog Neuropsychopharmacol Biol Psychiatry; 1984; 8(3):397-409. PubMed ID: 6592676
[TBL] [Abstract][Full Text] [Related]
29. Acute and subacute CNS effects of milacemide in elderly people: double-blind, placebo-controlled quantitative EEG and psychometric investigations.
Saletu B; Grünberger J; Linzmayer L
Arch Gerontol Geriatr; 1986 Oct; 5(3):165-81. PubMed ID: 3541816
[TBL] [Abstract][Full Text] [Related]
30. Classification and bioavailability studies with WE 941 by quantitative pharmaco-EEG and clinical analyses.
Saletu B; Grünberger J; Volavka J; Berner P
Arzneimittelforschung; 1979; 29(4):700-4. PubMed ID: 582772
[TBL] [Abstract][Full Text] [Related]
31. Interactions of alcohol with amitriptyline, fluoxetine and placebo in normal subjects.
Allen D; Lader M
Int Clin Psychopharmacol; 1989 Jan; 4 Suppl 1():7-14. PubMed ID: 2783702
[TBL] [Abstract][Full Text] [Related]
32. Enantioselective effects of levodropropizine and dropropizine on psychomotor functions in normal volunteers: a placebo-controlled, double-blind comparative study.
Gatti G; Barzaghi N; Dominijanni R; Cordaro C; Perucca E
Drugs Exp Clin Res; 1993; 19(1):33-9. PubMed ID: 8223138
[TBL] [Abstract][Full Text] [Related]
33. Psychomotor performance in healthy young adult volunteers receiving lormetazepam and placebo: a single-dose, randomized, double-blind, crossover trial.
Fabbrini M; Frittelli C; Bonanni E; Maestri M; Manca ML; Iudice A
Clin Ther; 2005 Jan; 27(1):78-83. PubMed ID: 15763608
[TBL] [Abstract][Full Text] [Related]
34. Effects of the novel neuroprotective agent, riluzole, on human brain function and behavior: I. Double-blind, placebo-controlled EEG mapping and psychometric studies under normoxia.
Saletu B; Grünberger J; Anderer P; Linzmayer L
Methods Find Exp Clin Pharmacol; 1996; 18(1):55-66. PubMed ID: 8721257
[TBL] [Abstract][Full Text] [Related]
35. Antidepressants and driver impairment: empirical evidence from a standard on-the-road test.
Ramaekers JG
J Clin Psychiatry; 2003 Jan; 64(1):20-9. PubMed ID: 12590619
[TBL] [Abstract][Full Text] [Related]
36. Topographic brain mapping of EEG in neuropsychopharmacology--Part II. Clinical applications (pharmaco EEG imaging).
Saletu B; Anderer P; Kinsperger K; Grünberger J
Methods Find Exp Clin Pharmacol; 1987 Jun; 9(6):385-408. PubMed ID: 2888937
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics and CNS pharmacodynamics of the 5-HT1A agonist buspirone in humans following acute L-tryptophan depletion challenge.
Jagannathan V; Venitz J
Methods Find Exp Clin Pharmacol; 1997 Jun; 19(5):351-62. PubMed ID: 9379784
[TBL] [Abstract][Full Text] [Related]
39. The pharmacokinetics of nomifensine. Comparison of pharmacokinetics and pharmacodynamics using computer pharmaco-EEG.
Saletu B; Grünberger J; Linzmayer L; Taeuber K
Int Pharmacopsychiatry; 1982; 17 Suppl 1():43-72. PubMed ID: 7129805
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetic and pharmacodynamic properties of buprenorphine after a single intravenous administration in healthy volunteers: a randomized, double-blind, placebo-controlled, crossover study.
Escher M; Daali Y; Chabert J; Hopfgartner G; Dayer P; Desmeules J
Clin Ther; 2007 Aug; 29(8):1620-31. PubMed ID: 17919544
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
